{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:07:09Z","timestamp":1787677629012,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1007\/s11906-002-0069-3","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:11:30Z","timestamp":1180123890000},"page":"387-393","source":"Crossref","is-referenced-by-count":39,"title":["Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy"],"prefix":"10.1007","volume":"4","author":[{"given":"Hans-Henrik","family":"Parving","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hovind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"69_CR1","first-page":"1731","volume-title":"The Kidney","author":"H-H Parving","year":"2000","unstructured":"Parving H-H, \u00d8sterby R, Ritz E: Diabetic nephropathy. In The Kidney, edn 6. Edited by Brenner BM. Philadelphia: WB Saunders; 2000:1731\u20131773.","edition":"edn 6"},{"key":"69_CR2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","volume":"271","author":"GC Viberti","year":"1994","unstructured":"Viberti GC, Mogensen CE, Groop L, Pauls JF, the European Microalbuminuria Captopril Study Group: Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994, 271:275\u2013279.","journal-title":"JAMA"},{"key":"69_CR3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0002-9343(99)80226-5","volume":"99","author":"LM Laffel","year":"1995","unstructured":"Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin- converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995, 99:497\u2013504.","journal-title":"Am J Med"},{"key":"69_CR4","first-page":"327","volume":"7","author":"MJ O\u2019Donnell","year":"1993","unstructured":"O\u2019Donnell MJ, Rowe BR, Lawson N, et al.: Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993, 7:327\u2013332.","journal-title":"J Hum Hypertens"},{"key":"69_CR5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diacare.21.1.104","volume":"21","author":"G Crepaldi","year":"1998","unstructured":"Crepaldi G, Carta Q, Deferrari G, et al.: Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998, 21:104\u2013110.","journal-title":"Diabetes Care"},{"key":"69_CR6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","volume":"349","author":"The EUCLID Study Group","year":"1997","unstructured":"The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349:1787\u20131792.","journal-title":"Lancet"},{"key":"69_CR7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.303.6794.81","volume":"303","author":"ER Mathiesen","year":"1991","unstructured":"Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br Med J 1991, 303:81\u201387.","journal-title":"Br Med J"},{"key":"69_CR8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.297.6656.1092","volume":"297","author":"M Marre","year":"1988","unstructured":"Marre M, Chatellier G, Leblanc H, et al.: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988, 297:1092\u20131095.","journal-title":"Br Med J"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bmj.302.6770.210","volume":"302","author":"Melbourne Diabetic Nephropathy Study Group","year":"1991","unstructured":"Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991, 302:210\u2013216.","journal-title":"Br Med J"},{"key":"69_CR10","first-page":"A5","volume":"41","author":"E Ebbehoj","year":"1998","unstructured":"Ebbehoj E, Poulsen PL, Nosadini R: Early ACE-i intervention in microalbuminuria:24h BP, renal function, and exercise changes [abstract]. Diabetologia 1998, 41:A5.","journal-title":"Diabetologia"},{"key":"69_CR11","first-page":"843","volume":"50","author":"LA Barnes","year":"2001","unstructured":"Barnes LA, Bilous RW, Tate H, Remuzzi G: The effect of three years of antihypertensive therapy in renal structure in type 1 diabetic patients with albuminuria. Diabetologia 2001, 50:843\u2013850.","journal-title":"Diabetologia"},{"key":"69_CR12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/diacare.24.5.919","volume":"24","author":"M Bojestig","year":"2001","unstructured":"Bojestig M, Karlberg BE, Lindstrom T, Nystrom FH: Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001, 24:919\u2013924.","journal-title":"Diabetes Care"},{"key":"69_CR13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2337\/diacare.23.12.1823","volume":"23","author":"The ATLANTIS Study Group","year":"2000","unstructured":"The ATLANTIS Study Group: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients wihout hypertension. Diabetes Care 2000, 23:1823\u20131829.","journal-title":"Diabetes Care"},{"key":"69_CR14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","volume":"134","author":"The ACE Inhibitors in Diabetic Nephropathy Trialist Group","year":"2001","unstructured":"The ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann Intern Med 2001, 134:370\u2013379. This meta-analysis includes all 12 studies dealing with the effect of ACE inhibitors in normotensive, microalbuminuric type 1 diabetic patients.","journal-title":"Ann Intern Med"},{"key":"69_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","volume":"319","author":"ER Mathiesen","year":"1999","unstructured":"Mathiesen ER, Hommel E, Hansen HP, et al.: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999, 319:24\u201325.","journal-title":"Br Med J"},{"key":"69_CR16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM198402093100605","volume":"310","author":"CE Mogensen","year":"1984","unstructured":"Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984, 310:356\u2013360.","journal-title":"N Engl J Med"},{"key":"69_CR17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","volume":"118","author":"M Ravid","year":"1993","unstructured":"Ravid M, Savin H, Jutrin I, et al.: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577\u2013581.","journal-title":"Ann Intern Med"},{"key":"69_CR18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253\u2013259. This substudy deals with the beneficial effect of ACE inhibitors on vascular endpoints in diabetic patients in the HOPE study.","journal-title":"Lancet"},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.HYP.21.6.786","volume":"21","author":"Y Lacourciere","year":"1993","unstructured":"Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993, 21:786\u2013794.","journal-title":"Hypertension"},{"issue":"Suppl 45","key":"69_CR20","first-page":"S150","volume":"45","author":"HE Lebovitz","year":"1994","unstructured":"Lebovitz HE, Wiegmann TB, Cnaan A, et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994, 45(Suppl 45):S150-S155.","journal-title":"Kidney Int Suppl"},{"key":"69_CR21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0895-7061(95)00162-I","volume":"8","author":"R Trevisan","year":"1995","unstructured":"Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive noninsulin- dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995, 8:876\u2013883.","journal-title":"Am J Hypertens"},{"key":"69_CR22","first-page":"185","volume":"10","author":"C-D Agardh","year":"1996","unstructured":"Agardh C-D, Garcia-Puig J, Charbonnel B, et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996, 10:185\u2013192.","journal-title":"J Hum Hypertens"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1523-1755.2000.00879.x","volume":"57","author":"JC Chan","year":"2000","unstructured":"Chan JC, Ko GT, Leung DH, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57:590\u2013600.","journal-title":"Kidney Int"},{"key":"69_CR24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, et al.: Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597\u2013603.","journal-title":"Diabetes Care"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Br Med J 1998, 317:713\u2013720. This substudy indicates a similar beneficial effect on vascular endpoints of ACE inhibitors versus \u00df-blockers in hypertensive type 2 diabetic patients.","journal-title":"Br Med J"},{"key":"69_CR26","first-page":"B54","volume":"23","author":"RO Estacio","year":"2000","unstructured":"Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23:B54-B64.","journal-title":"Diabetes Care"},{"key":"69_CR27","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"H-H Parving","year":"2001","unstructured":"Parving H-H, Lehnert H, Br\u00f6chner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870\u2013878. This study demonstrates that an angiotensin II receptor blocker has a renoprotective effect above and beyond its beneficial impact on blood pressure.","journal-title":"N Engl J Med"},{"key":"69_CR28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study [in process citation]. Br Med J 2000, 321:1440\u20131444.","journal-title":"Br Med J"},{"key":"69_CR29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","volume":"353","author":"P Gaede","year":"1999","unstructured":"Gaede P, Vedel P, Parving H-H, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999, 353:617\u2013622.","journal-title":"Lancet"},{"key":"69_CR30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(95)91747-0","volume":"346","author":"CE Mogensen","year":"1995","unstructured":"Mogensen CE, Keane WF, Bennett PH, et al.: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995, 346:1080\u20131084.","journal-title":"Lancet"},{"key":"69_CR31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/diacare.25.4.742","volume":"25","author":"American Diabetes Association","year":"2002","unstructured":"American Diabetes Association: Diabetic nephropathy. Diabetes Care 2002, 25:585\u2013589.","journal-title":"Diabetes Care"},{"key":"69_CR32","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199611283352212","volume":"335","author":"H-H Parving","year":"1996","unstructured":"Parving H-H: Initiation and progression of diabetic nephropathy. N Engl J Med 1996, 335:1682\u20131683.","journal-title":"N Engl J Med"},{"key":"69_CR33","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1056\/NEJM199611283352203","volume":"335","author":"RG Nelson","year":"1996","unstructured":"Nelson RG, Bennett PH, Beck GJ, et al.: Development and progression of renal disease in Pima indians with noninsulin- dependent diabetes mellitus. N Engl J Med 1996, 335:1636\u20131642.","journal-title":"N Engl J Med"},{"key":"69_CR34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","volume":"156","author":"M Ravid","year":"1996","unstructured":"Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996, 156:286\u2013289.","journal-title":"Arch Intern Med"},{"key":"69_CR35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2337\/diacare.20.10.1576","volume":"20","author":"J Ahmad","year":"1997","unstructured":"Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997, 20:1576\u20131581.","journal-title":"Diabetes Care"},{"key":"69_CR36","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1046\/j.1523-1755.2001.00020.x","volume":"60","author":"HH Parving","year":"2001","unstructured":"Parving HH: Diabetic nephropathy: prevention and treatment. Kidney Int 2001, 60:2041\u20132055.","journal-title":"Kidney Int"},{"key":"69_CR37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-5491.1984.tb01915.x","volume":"1","author":"RJ Jarrett","year":"1984","unstructured":"Jarrett RJ, Viberti GC, Argyropoulos A, et al.: Microalbuminuria predicts mortality in non-insulin-dependent diabetes. Diabetic Med 1984, 1:17\u201319.","journal-title":"Diabetic Med"},{"key":"69_CR38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diab.41.6.736","volume":"41","author":"MB Mattock","year":"1992","unstructured":"Mattock MB, Morrish NJ, Viberti GC, et al.: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992, 41:736\u2013741.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"69_CR39","first-page":"A34","volume":"35","author":"JM MacLeod","year":"1992","unstructured":"MacLeod JM, Lutale J, Marshall SM: Excess mortality in type 2 diabetic patients with minimal elevation of albumin excretion. Diabetologia 1992, 35(Suppl 1):A34.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"69_CR40","first-page":"S4","volume":"10","author":"AB Atkinson","year":"1993","unstructured":"Atkinson AB, Beatty OL, Ritchie CM, et al.: Clinic urinary albumin concentration predicts both mortality and progression to nephropathy in NIDDM: results of an 8 year prospective study. Diabetic Med 1993, 10(Suppl 1):S4.","journal-title":"Diabetic Med"},{"issue":"Suppl 1","key":"69_CR41","first-page":"A207","volume":"36","author":"M-A Gall","year":"1993","unstructured":"Gall M-A, Borch-Johnsen K, Nielsen FS, et al.: Micro- and macroalbuminuria as predictors of mortality in non-insulindependent diabetes. Diabetologia 1993, 36(Suppl 1):A207.","journal-title":"Diabetologia"},{"key":"69_CR42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1464-5491.1992.tb01861.x","volume":"9","author":"H Stiegler","year":"1992","unstructured":"Stiegler H, Sandl E, Schulz K, et al.: Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabetic Med 1992, 9:646\u2013653.","journal-title":"Diabetic Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-002-0069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-002-0069-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-002-0069-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:04Z","timestamp":1559434564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-002-0069-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s11906-002-0069-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}